2021-04-13 · About DIAMYD MEDICAL AB Diamyd Medical Aktiebolag produces pharmaceuticals and medical vaccines. The Company develops diabetes vaccines for the treatment and prevention of auto-immune diabetes.

Diamyd Medical Aktiebolag LEI 5493003NP2HNQDEKB804 Diamyd Therapeutics AB Diamyd Therapeutics Aktiebolag. Legal Address. Kungsgatan 29 Stockholm SE-AB SE 111 56. Headquarters Address. Kungsgatan 29 Stockholm SE-AB SE 111 56. External Public Records. LEI: 5493003NP2HNQDEKB804. Diamyd Medical Aktiebolag. LEI Registration Details.

Diamyd Medical is a Swedish diabetes company active in the field of pharmaceutical development. Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based Therapy (ABT) based on the Diamyd Medical Aktiebolag: Org.nr: 556242-3797: Typ: Publikt aktiebolag Nasdaq Nordic: DMYD B: Huvudkontor: Stockholm, Sverige: Nyckelpersoner: Erik Nerpin Styrelseordförande Ulf Hannelius Vd: Bransch: Läkemedelsföretag: Antal anställda: 6 – December 2015: Historia; Grundat: 1996: Grundare: Anders Essen-Möller: Ekonomi; Omsättning 1,212 miljoner SEK: Rörelseresultat Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden +46 8 661 00 26 +46 8 661 63 68 info@diamyd.com Diamyd Medical Aktiebolag,556242-3797 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, varumärken, adress mm för Diamyd Medical Aktiebolag Sök Få mer bolagsinformation Diamyd Medical Aktiebolag produces pharmaceuticals and medical vaccines. The Company develops diabetes vaccines for the treatment and prevention of auto-immune diabetes. Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes Diamyd Medical AB Financial Reports. Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden +46 8 661 00 26 Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se For Diamyd Medical has contracted the global contract research organization (CRO) ICON plc for DIAGNODE-3, a placebo-controlled Phase III precision medicine trial with the diabetes vaccine Diamyd®.

{{ chapter.num }}. {{ chapter.name }} Apr 21, 2021 CEO Ulf Hannelius has been invited to give a talk at the "Precision medicine - From patient to lab and back again" conference organized by the Apr 15, 2021 Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB. Diamyd Medical's B-share is traded on Nasdaq Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. Its pipeline Apr 2, 2015 Diamyd Medical (Nasdaq Stockholm First North Ticker: DMYD B) in the stem cell company Cellaviva AB, which is establishing a Swedish Diamyd Medical AB, Financial hearing, 2020. March 11th 2020 10:45 (Europe/ Stockholm). Language: Swedish. Speaker: CEO Ulf Hannelius. Moderator:.

Nyckeltal för Diamyd Medical Aktiebolag Skriv ut Information 2019-08 2018-08 2017-08 2016-08 Valuta KSEK KSEK KSEK KSEK Bokslutsperiodens längd, månader 12 12 12 12

The Company develops diabetes vaccines for the treatment and prevention of auto-immune diabetes. Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes Diamyd Medical AB Financial Reports.

Diamyd Medical B. ISIN SE0005162880; Closed. REAL-TIME. 17:29:44 CET. Last traded on 2021-04-27 00:00:00. 26.4. -0.06 (-0.2268%). Currency in SEK

Antalet anställda är oförändrat sedan året innan.
Hur mycket koldioxid släpper min bil ut

The share is listed on Nasdaq Stockholm First Stockopedia rates Diamyd Medical AB as a Highly Speculative Sucker Stock . 1 brokers rate it as a 'Buy'. Click to view STO:DMYD B's StockReport. Osta osaketta Diamyd Medical AB ser.

Diamyd Medical Press Releases. Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden +46 8 661 00 26

Läs mer.

Diamyd Medical Aktiebolag 556242-3797 (Stockholm) Översikt Telefonnummer Adresser Styrelse och koncern Verklig huvudman Nyckeltal Kreditupplysning Nu kan du hämta data om personer, företag, telefonnummer, bostäder och fordon via API eller fil.

The latest Diamyd Medical AB NPV B share price. View recent trades and share price information for Diamyd Medical AB NPV B. Security and exchange commission filings for Diamyd Medical Ab. Insider trades, quarterly, and annual reports.

För ytterligare information, vänligen kontakta: info@mertiva.se. Om Mertiva Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta Nyckeltal för Diamyd Medical Aktiebolag Skriv ut Information 2019-08 2018-08 2017-08 2016-08 Valuta KSEK KSEK KSEK KSEK Bokslutsperiodens längd, månader 12 12 12 12 Diamyd Medical Aktiebolag 086610026 08-661 00 26 KUNGSGATAN 29 111 56 Stockholm Om oss Annonsera Villkor Om cookies Integritet Bloggen Ta bort uppgifter Mertiva AB (former Diamyd Medical) primarily consists of holdings in liquid assets and holdings in Protein Sciences Corporation and Mercodia AB. Mertiva (former Diamyd Medical) shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL). Diamyd Medical är verksamma inom diabetesforskning. Bolaget arbetar aktivt med att förbättra livet för patienter med diabetes.